ICPO Foundation awards ICPO Academy stipends to the Department of Nuclear Medicine at Osaka University Hospital
2024年5月6日 - 7:30PM
Prof. Dr. Tadashi Watabe, Medical Doctor at Osaka
University Hospital and Associate Professor at Osaka University, is
an active member of the ICPO Foundation
May 6, 2024 – Wiesbaden, Germany, and Osaka,
Japan. Today, the International Centers for
Precision Oncology (ICPO) Foundation announced a cooperation with
the Department of Nuclear Medicine at the Osaka University
Hospital. ICPO offers industry-funded stipends for the ICPO Academy
for Theranostics to dedicated healthcare professionals worldwide.
"Through this agreement, we have the opportunity to provide
advanced training in theranostics to team members of the Department
for Nuclear Medicine at Osaka University Hospital. This will help
close the gap of professionals needed for this innovative cancer
therapy of Radiomolecular Precision Oncology worldwide," says Odile
Jaume, CEO ICPO Foundation. Prof. Watabe is an active member of the
ICPO community and supports international congresses and workshops
such as the Theranostics World Congress or the upcoming workshop
"Translational Nuclear Medicine: Theory and Practice" in
cooperation with Prof. Frederik Giesel, Chief Physician and
Director of the Clinic for Nuclear Medicine at the University
Hospital Düsseldorf.
Osaka University Hospital, known for its dedication to
excellence, places significant emphasis on research and development
in the medical field. The hospital actively engages in the
development and application of cutting-edge medical practices,
adhering to rigorous regulations governing clinical research, such
as the Clinical Trials Act. Nuclear Medicine serves as a
cornerstone of Osaka University Hospital's diagnostic and
therapeutic prowess. Equipped with state-of-the-art PET-CT and
SPECT-CT scanners, the hospital specializes in diagnostic nuclear
medicine and radiopharmaceutical-based treatments.
Dr. Tadashi Watabe, Associate Professor at Osaka University's
Department of Nuclear Medicine, leads groundbreaking research in
targeted alpha therapy. He is the Principal Investigator for the
Alpha-T1 trial for thyroid cancer using [At-211] NaAt, and upcoming
trials for castration-resistant prostate cancer using [At-211]
PSMA-5. With over 100 peer-reviewed publications, his work focuses
on preclinical development of At-211 and Ac-225 therapies, and
theranostics with FAPI inhibitors. "We are deeply grateful to the
ICPO Foundation for this collaboration. The training provided by
the ICPO Academy will not only enhance the qualifications of our
team in the field of theranostics but also underscore the value of
our contributions to Radiomolecular Precision Oncology," explains
Prof. Tadashi Watabe.
The main objective of the ICPO Academy for Theranostics is to
disseminate knowledge in Radiomolecular Precision Oncology to
improve the outcome of a patient treated with radiopharmaceutical
therapies. The academy offers a comprehensive online educational
program, developed by the ICPO Foundation, and powered by its
global community of experts. It features over 50 hours of content
taught by over 30 leaders and experts. The primary audiences of the
ICPO Academy for Theranostics are clinicians, researchers,
physicists, and radiochemists as well as nurses and technologists,
who seek to integrate Radiomolecular Precision Oncology in patient
care. The content is available in different languages.
The curriculum by the ICPO Academy for Theranostics has been
developed under the guidance of its President, Prof. Richard P.
Baum, a world leader and pioneer in nuclear medicine and
Radiomolecular Precision Oncology, together with prominent Pillar
Leaders, international experts in their respective fields, namely
Prof. Vikas Prasad (Radiomolecular Precision Oncology), Prof.
Thomas Beyer (Medical Physics), Prof. Frank Rösch (Radiochemistry),
Linda Gardner and Josh Mailman (both Nursing and patient
management).
About ICPO Foundation The International Centers
for Precision Oncology Foundation (ICPO) is a non-profit
organization established in 2019 under German law by leading
international medical practitioners and life sciences
entrepreneurs. Recognizing a paradigm shift in cancer care from one
size fits all to a personalized approach, the ICPO Foundation is
helping to build momentum to scale global patient access to
Radiomolecular Precision Oncology to support this shift. Therefore,
the ICPO Foundation aims to develop an international network of
physical diagnostic and therapeutic Centers for Precision Oncology
organized in a Social Franchise model based on shared know-how,
certified education with the ICPO Academy for Theranostics, and
design and process standardization that enables best clinical
practice globally. Furthermore, it is the ICPO Foundation's
objective to empower its Centers by embedding them in a highly
inclusive Community that spearheads its model and lives up to the
Precision Oncology promise by making it available to all patients
in need, irrespective of country or social status.
Learn more about the ICPO Foundation at www.icpo.foundation and
about the ICPO Academy for Theranostics at
www.theranostics.academy.
Media contact ICPO Foundation
Susanne SimonHead of Communication & CommunityEmail:
susanne.simon@icpo.foundationPhone: + 49 172
8666093www.icpo.foundation